2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3868 Spatial single cell profiling reveals heterogeneity in proliferative aggregates and distinct T cell subpopulations within the chronic lymphocytic leukaemia lymph node tumour microenvironment

Paul Buckley, PhD, Stella Bouziana, MD, PhD2, Timothy Woo3, Hanna Mohamed4, Aamina Ahmed5, Liron Barnea Slonim6, Cynthia Bishop7, Robbert Hoogeboom8, Piers E M Patten, MB ChB PhD9
1 King's College London, London, United Kingdom
2 King's College London, London, United Kingdom
3 King's College London, London, United Kingdom
4 King's College London, London, United Kingdom
5 King's College London, London, United Kingdom
6 King’s College Hospital NHS Foundation Trust, London, United Kingdom
7 Guys & Saint Thomas Nhs Foundation Trust, London, United Kingdom
8 King's College London, London, United Kingdom
9 King's College London, London, United Kingdom

Chronic lymphocytic leukaemia (CLL) is a dynamic and clinically heterogeneous disease sustained by a permissive lymph node (LN) tumour microenvironment (TME). Alongside genomic complexities, TME differences may contribute to this clinical heterogeneity. Proliferative aggregates in CLL-LNs (histologically described as proliferation centres) play a major role in disease pathogenesis, yet detailed single cell spatial characterisation of their architecture, and the wider LN TME, remains limited. Nonetheless, prior work has established recurrent accessory populations including T cells, macrophages and other cells. We therefore hypothesised that the CLL TME would comprise conserved architectural features across patients, including reliable presence of T cells and macrophages among both Ki67+ and Ki67- B cells. Given the clinical heterogeneity of CLL however, we investigated the extent that TME features, with a focus on proliferative aggregates, were conserved within and between patient samples.

 

We thus optimised a 31-plex panel to identify tumor, immune and stromal cells. LN biopsies from 7 untreated CLL patients were stained with metal isotope-tagged primary antibodies and imaged by Hyperion imaging mass cytometry, generating 18 regions of interest (ROI). Deep learning segmentation resolved 316,008 cells.

 

Phenotyping identified B-cell, T-cell, macrophage, stromal and wider subpopulations. First, we examined neighborhood architecture with 8 distinct CNs identified. Four of seven patients’ tumours shared a B-cell scaffold composed of four neighborhoods. These CNs differed predominantly in B-cell phenotype, rather than accessory immune content (accessory populations in these CNs varied by <4%). Furthermore, these four patients exhibited variable configuration of these CNs: indeed, the abundance of each CN comprising this shared scaffold differed considerably across patients. The remaining three patients exhibited distinct architectures, dominated respectively by a naïve CD8+ T-cell rich CN, a CD4+ memory/checkpoint environment and a CD45RA-CD27+ B cell phenotype.

 

We next examined areas enriched for Ki67+ B-cells, utilising density-based spatial clustering to define 241 regions (>=4 cells/30um) of Ki67+ B-cells and assessed cellular composition within 50um of these cells. Although the global abundance of Ki67+ B-cells varied considerably between patients (0.192%-9.64% / ROI), the lineages surrounding them were consistent. B cells were present in 100% (241/24) of regions, CD4+ T cells in 99%, CD8+ T cells in 93%, detectable stroma in 86% and macrophages in 80%. B cells were markedly enriched within 50um of these cells vs. background tissue (β = 1.21, FDR < 0.001) and CD4+ T cells were also elevated (β = 0.77, FDR = 0.054). We observed that Ki67hi CD4+ and CD8+ T cells were typically closer to Ki67+B cells than their Ki67lo T cell counterparts (both p<0.001). In >70% of aggregates, we observed CD45RO+CD45RA+CD27+CD4+ and CD8+ T-cells within 15um of these Ki67 clusters. Notably, the presence of most T-cell phenotypes near Ki67+B cells typically varied between patients whereas CD45RO+CD45RA+CD27+CD4+/CD8+ T cells and naïve T-cell subsets varied region-to-region within patients. These data suggest that T-cell phenotypic composition proximal to proliferative regions is patient-specific for some subsets and locally determined for others. Finally, we observed that a spatial context capturing the interface of two neighborhoods where Ki67+CD20+CD79a+ reside was the second most common context across samples.

 

Our data indicate an architectural scaffold within CLL, built on B-cell-rich neighborhoods infiltrated with accessory immune cells. Notably, a subset of patients had individually distinct microenvironments. Despite marked between-patient variation in proliferative burden, the presence of lineages immediately surrounding Ki67+ B cells was consistent, while the interface between diverse B-cell aggregates and Ki67+ B cells may reflect histological proliferation centres. Specific T-cell subpopulations showed strikingly variable presence and distribution, although a common CD45RO+CD45RA+CD27+ phenotype of both CD4+ and CD8+ T cells was found positioned adjacent to Ki67+ B cells. While validation using confocal microscopy of such cells is ongoing, we hypothesise that these T cell subpopulations may reflect activated and differentiated accessory subsets and note that they are well-positioned to support CLL cell survival.

Piers E M Patten, MB ChB PhD: AstraZeneca - Honoraria; BeOne - Honoraria; BeOne - Honoraria; Astra Zeneca - Honoraria; Adaptive Biotechnologies - Honoraria; Eli Lilly - Honoraria; Lilly - Honoraria; Abbvie - Honoraria; AbbVie - Honoraria; Janssen - Honoraria; BeOne - Research Funding; AstraZeneca - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony)